TD Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.54M | Hold |
158,416
| – | – | 0.01% | 715 |
|
|
2025
Q4 | $8.31M | Sell |
158,416
-16,200
| -9% | -$970K | 0.01% | 703 |
|
|
2025
Q3 | $11.3M | Sell |
174,616
-53,800
| -24% | -$3.09M | 0.01% | 629 |
|
|
2025
Q2 | $11.1M | Sell |
228,416
-13,904
| -6% | -$538K | 0.01% | 619 |
|
|
2025
Q1 | $8.25M | Buy |
242,320
+1,876
| +0.8% | +$79.5K | 0.01% | 686 |
|
|
2024
Q4 | $9.46M | Buy |
240,444
+80,800
| +51% | +$3.82M | 0.01% | 658 |
|
|
2024
Q3 | $7.55M | Hold |
159,644
| – | – | 0.01% | 695 |
|
|
2024
Q2 | $8.62M | Sell |
159,644
-7,150
| -4% | -$414K | 0.01% | 645 |
|
|
2024
Q1 | $11.4M | Sell |
166,794
-59,068
| -26% | -$4.23M | 0.01% | 605 |
|
|
2023
Q4 | $14.1M | Sell |
225,862
-14,600
| -6% | -$807K | 0.01% | 556 |
|
|
2023
Q3 | $10.9M | Buy |
240,462
+27,387
| +13% | +$1.41M | 0.01% | 571 |
|
|
2023
Q2 | $12M | Buy |
213,075
+3,069
| +1% | +$174K | 0.01% | 555 |
|
|
2023
Q1 | $9.5M | Buy |
210,006
+28,179
| +15% | +$1.37M | 0.01% | 619 |
|
|
2022
Q4 | $7.39M | Buy |
181,827
+66,536
| +58% | +$3.53M | 0.01% | 658 |
|
|
2022
Q3 | $7.43M | Buy |
115,291
+11,630
| +11% | +$843K | 0.01% | 661 |
|
|
2022
Q2 | $6.3M | Buy |
103,661
+71,636
| +224% | +$4.21M | 0.01% | 721 |
|
|
2022
Q1 | $2.01M | Sell |
32,025
-2,248
| -7% | -$141K | ﹤0.01% | 1084 |
|
|
2021
Q4 | $2.6M | Buy |
34,273
+3,876
| +13% | +$339K | ﹤0.01% | 1073 |
|
|
2021
Q3 | $3.4M | Hold |
30,397
| – | – | ﹤0.01% | 931 |
|
|
2021
Q2 | $3.68M | Sell |
30,397
-999
| -3% | -$121K | ﹤0.01% | 917 |
|
|
2021
Q1 | $3.83M | Sell |
31,396
-312
| -1% | -$47.1K | ﹤0.01% | 903 |
|
|
2020
Q4 | $4.86M | Buy |
+31,708
| New | +$3.75M | 0.01% | 794 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
